rg7795 rg7795 rg7795 (previously ana773) is an antiviral drug candidate that as of 2015 had been in phase ii trials in hepatitis b. it is an orally-available prodrug of isatoribine, that was under development by anadys pharmaceuticals when it was acquired by roche in 2011. its active metabolite is an agonist of tlr7; activation of tlr7 causes secretion of endogenous type 1 interferons, which have antiviral activity. chemical structure of isatoribine rg7795clinical dataother namesrg-7795; ana773; ana-773legal statuslegal status investigational identifierscas number892498-64-5 ypubchem cid11587892drugbankdb06329chemspider9762656uniiqti86134ylchemical and physical dataformulac12h14n4o5smolar mass326.33 g·mol−13d model (jsmol)interactive image smiles o=c1n(c=2c(s1)=cn=c(n)n2)3((oc(c)=o)c(co)o3) inchi inchi=1s/c12h14n4o5s/c1-5(18)20-7-2-6(4-17)21-10(7)16-9-8(22-12(16)19)3-14-11(13)15-9/h3,6-7,10,17h,2,4h2,1h3,(h2,13,14,15)/t6-,7+,10+/m0/s1key:hoomgtnenmzafp-nyncvsemsa-n as of 2021, development of rg7795 appears to be discontinued.